Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Present status of human papillomavirus vaccine development and implementation.

Herrero R, González P, Markowitz LE.

Lancet Oncol. 2015 May;16(5):e206-16. doi: 10.1016/S1470-2045(14)70481-4. Review.

PMID:
25943065
2.

[HPV prophylactic vaccines].

Konopnicki D.

Rev Med Brux. 2014 Sep;35(4):338-42. French.

PMID:
25675641
3.

[Cervical cancer: particularities in HIV patients].

Grellier N, Quéro L.

Bull Cancer. 2014 Nov;101(11):1040-7. doi: 10.1684/bdc.2014.2034. Review. French.

PMID:
25418597
4.

Phase I study demonstrates safety and tolerability of radiofrequency ablation (RFA) of the anal mucosa.

Smulian AG, Moore DM, Robertson JC, Kralovic SM.

HIV Clin Trials. 2014 Jan-Feb;15(1):36-44. doi: 10.1310/hct1501-36.

PMID:
24525427
5.

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.

Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS.

J Infect Dis. 2014 Apr 15;209(8):1165-73. doi: 10.1093/infdis/jit657. Epub 2013 Nov 23.

6.

High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects.

Watson-Jones D, Baisley K, Brown J, Kavishe B, Andreasen A, Changalucha J, Mayaud P, Kapiga S, Gumodoka B, Hayes RJ, de Sanjosé S.

Sex Transm Infect. 2013 Aug;89(5):358-65. doi: 10.1136/sextrans-2012-050685. Epub 2013 Mar 13.

7.

The application of Kingdon's Multiple Streams Theory for human papillomavirus-related anal intraepithelial neoplasia.

Walhart T.

J Adv Nurs. 2013 Nov;69(11):2413-22. doi: 10.1111/jan.12108. Epub 2013 Feb 28.

PMID:
23448572
8.

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, Kapiga S, Mayaud P, Hayes R, Lebacq M, Herazeh M, Thomas F, Descamps D.

J Infect Dis. 2013 Jun 1;207(11):1753-63. doi: 10.1093/infdis/jis619. Epub 2012 Dec 13.

9.

Human papillomavirus, human immunodeficiency virus and immunosuppression.

Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J.

Vaccine. 2012 Nov 20;30 Suppl 5:F168-74. doi: 10.1016/j.vaccine.2012.06.045. Review.

PMID:
23199960
10.

Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, Lee JY, Darragh TM, Da Costa M, Panther L, Aboulafia D, Palefsky JM.

AIDS. 2013 Feb 20;27(4):545-51. doi: 10.1097/QAD.0b013e32835a9b16.

11.

Safety against cervical precancer and cancer following negative human papillomavirus and Papanicolaou test results in human immunodeficiency virus-infected women.

Castle PE, Fetterman B, Poitras N, Lorey T, Kinney W.

Arch Intern Med. 2012 Jul 9;172(13):1041-3. doi: 10.1001/archinternmed.2012.1744. No abstract available.

PMID:
22641193
12.

Perceptions of HPV and cervical cancer among Haitian immigrant women: implications for vaccine acceptability.

Kobetz E, Menard J, Hazan G, Koru-Sengul T, Joseph T, Nissan J, Barton B, Blanco J, Kornfeld J.

Educ Health (Abingdon). 2011 Dec;24(3):479. Epub 2011 Dec 7.

PMID:
22267344
13.

Human papillomavirus, cancer and vaccination.

Heard I.

Curr Opin HIV AIDS. 2011 Jul;6(4):297-302. doi: 10.1097/COH.0b013e328347335d. Review.

PMID:
21519247
14.

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

J Infect Dis. 2010 Oct 15;202(8):1246-53. doi: 10.1086/656320.

15.

Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.

Richel O, Wieland U, de Vries HJ, Brockmeyer NH, van Noesel C, Potthoff A, Prins JM, Kreuter A.

Br J Dermatol. 2010 Dec;163(6):1301-7. doi: 10.1111/j.1365-2133.2010.09982.x. Epub 2010 Nov 4.

PMID:
20716208
16.

Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review.

Louie KS, de Sanjose S, Mayaud P.

Trop Med Int Health. 2009 Oct;14(10):1287-302. doi: 10.1111/j.1365-3156.2009.02372.x. Review.

18.

A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus.

Anderson JS, Hoy J, Hillman R, Barnden M, Eu B, McKenzie A, Gittleson C.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):371-81. doi: 10.1097/QAI.0b013e3181b7354c.

PMID:
19661810
19.

Nuclear factor-kappa B links carcinogenic and chemopreventive agents.

Ralhan R, Pandey MK, Aggarwal BB.

Front Biosci (Schol Ed). 2009 Jun 1;1:45-60. Review.

PMID:
19482682
20.

Prevalence status and association with human papilloma virus of anal squamous proliferative lesions in a patient sample in Taiwan.

Tsai TF, Kuo GT, Kuo LT, Hsiao CH.

Sex Transm Dis. 2008 Aug;35(8):721-4. doi: 10.1097/OLQ.0b013e3181705878.

PMID:
18650771
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk